Highlights

  • Ceryvyn Therapeutics redirected its single lead asset towards LAM following unsuccessful late-stage trials in wet age-related macular degeneration.
  • The company's stage-gated programme aims to reach initial proof-of-concept using existing cash, without raising capital for that work.
  • Cash fell to AUD 30.0mn at the financial year-end, while the company reported no debt and an operating loss.
  • The LAM programme remains preclinical, with formulation, device and regulatory uncertainty and no disclosed timelines for later development stages.

Ceryvyn Therapeutics Limited (ASX:CYV) is a small biotechnology company developing its single lead asset, CYV-101, for lymphangioleiomyomatosis (LAM), a rare, progressive lung disease. Formerly Opthea, the company redirected its programme after late-stage eye-disease trials failed. The board's reasoning, set out in the annual report signed on 31 August 2026, is that a stage-gated, inhaled programme can reach initial proof-of-concept on existing cash, without raising capital. LAM efficacy has not been clinically validated, and the programme remains preclinical.

From Opthea to an Inhaled LAM Programme

Opthea's Phase 3 COAST and ShORe trials, reported in March 2025, did not show efficacy for sozinibercept in wet age-related macular degeneration, which led to a trading halt. ASX trading then resumed on 3 June 2026. Shareholders approved the name change at a general meeting on 3 July 2026, the change took effect on 6 July 2026, and the company now trades under the ASX code CYV.

CYV-101 is a fusion protein designed to bind and neutralise VEGF-C and VEGF-D, signalling proteins linked to pathological lymphangiogenesis, the abnormal growth of lymphatic vessels. LAM mainly affects women, and current therapies do not offer a cure.

The company cites estimates of 5,000 to 7,000 diagnosed, addressable patients in the United States and 15,000 to 30,000 globally. It also points to earlier investment in manufacturing and development of about USD 120mn (AUD 179mn).

Accounting Gain Shapes the Annual Result

The results for the year ended 30 June 2026 include a substantial accounting item. Profit after tax was AUD 330.4mn, against a loss of AUD 251.1mn a year earlier, mainly because of an AUD 357.1mn gain on derecognition of the Development Funding Agreement. This followed an AUD 30.9mn settlement payment announced on 19 August 2025. The operating loss was AUD 11.9mn.

Cash stood at AUD 30.0mn at 30 June 2026, down from AUD 73.9mn a year earlier, with no debt. Net assets were AUD 29.6mn, compared with a deficit of AUD 306.9mn. No dividend was declared.

Stage-Gated Development and Remaining Risks

The programme has three stages, each subject to board review against scientific, operational and capital criteria. Stage 1, covering preclinical biology and inhalation studies including early animal safety and tolerability work, was described as on schedule in the June quarter.

Over roughly 18 months, the company aims to complete nebulised formulation development, finish preclinical work, engage regulators and assess target engagement, biological activity and safety in LAM patients. A Scientific Advisory Board will guide trial design, biomarkers and regulatory strategy. Timelines and costs for Stages 2 and 3 have not been disclosed, and no cash runway guidance has been given.

The programme depends on one asset. Moving to an inhaled route introduces formulation, device and regulatory uncertainty, and regulators may not accept the proposed endpoints. Rare-disease development also depends on small, hard-to-recruit patient populations. The R&D tax incentive is available only for FY26 and FY27, and further capital may be needed.

The company has pointed to completion of animal inhalation studies, regulatory engagement and a board decision on whether to begin Stage 2, none with a published date.